Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity

被引:104
作者
Höybye, C
Hilding, A
Jacobsson, H
Thorén, M
机构
[1] Karolinska Hosp & Inst, Dept Endocrinol & Diabetol, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp & Inst, Dept Radiol, SE-17176 Stockholm, Sweden
关键词
D O I
10.1210/jc.87.8.3590
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Previous investigations of adults with the Prader-Willi syndrome (PWS) are few and have demonstrated severe obesity with increased morbidity and mortality in cardiovascular disease. It is, thus, important to identify risk factors and, if possible, start prevention. We studied the clinical, genetic, endocrinological, and metabolic findings in 19 adult PWS patients (10 men; mean age, 25 yr). The PWS karyotype was demonstrated in 13 patients. The mean body mass index was 35.6 kgIM2, and total body fat was increased. Two thirds were biochemically hypogonadal. Fifty percent had severe GH deficiency (GHD). Four were hypertensive. One patient had heart failure and diabetes. Impaired glucose tolerance was seen in 4 patients, elevated homeostasis model assessment index in 9 patients, and modest dyslipidemia in 7. IGF-binding protein-1 correlated negatively with insulin levels. Four patients had osteoporosis, and 11 had osteopenia. There was no significant difference between the group with the PWS karyotype and the group without the karyotype in age, body mass index, waist/hip ratio, percent body fat, insulin values, homeostasis model assessment index, or lipid profile, except for lipoprotein(a), which was significantly higher in the group with the negative karyotype. IGF-I and lumbar spine bone mineral density were significantly lower in patients with genetic alteration, indicating a more severe GHD. The risk factors found in this study predicting cardiovascular disease are interpreted as secondary to GHD. These findings point to the importance of evaluating treatment of GHD in adults with PWS.
引用
收藏
页码:3590 / 3597
页数:8
相关论文
共 63 条
[41]   Leptin concentrations in Prader-Willi syndrome before and after growth hormone replacement [J].
Myers, SE ;
Davis, A ;
Whitman, BY ;
Santiago, JV ;
Landt, M .
CLINICAL ENDOCRINOLOGY, 2000, 52 (01) :101-105
[42]   GENETIC IMPRINTING SUGGESTED BY MATERNAL HETERODISOMY IN NONDELETION PRADER-WILLI SYNDROME [J].
NICHOLLS, RD ;
KNOLL, JHM ;
BUTLER, MG ;
KARAM, S ;
LALANDE, M .
NATURE, 1989, 342 (6247) :281-285
[43]  
NOZAKI Y, 1981, ACTA PAEDIATR JAPON, V23, P301
[44]   INCREASED CONCENTRATIONS OF SERUM LIPOPROTEIN(A) IN RESPONSE TO GROWTH-HORMONE TREATMENT [J].
OLIVECRONA, H ;
ERICSSON, S ;
BERGLUND, L ;
ANGELIN, B .
BRITISH MEDICAL JOURNAL, 1993, 306 (6894) :1726-1727
[45]   IMMUNOREACTIVE INSULIN AND GROWTH-HORMONE RESPONSES IN PATIENTS WITH PRADER-WILLI SYNDROME [J].
PARRA, A ;
CERVANTES, C ;
SCHULTZ, RB .
JOURNAL OF PEDIATRICS, 1973, 83 (04) :587-593
[46]   Adult patients with Prader-Willi syndrome:: clinical characteristics, life circumstances and growth hormone secretion [J].
Partsch, CJ ;
Lämmer, C ;
Gillessen-Kaesbach, G ;
Pankau, R .
GROWTH HORMONE & IGF RESEARCH, 2000, 10 :81-85
[47]   CROSS-REACTION OF SERUM SOMATOMEDIN-BINDING PROTEIN IN A RADIOIMMUNOASSAY DEVELOPED FOR SOMATOMEDIN-BINDING PROTEIN ISOLATED FROM HUMAN AMNIOTIC-FLUID [J].
POVOA, G ;
ROOVETE, A ;
HALL, K .
ACTA ENDOCRINOLOGICA, 1984, 107 (04) :563-570
[48]  
Prader A., 1956, SCHWEIZ MED WSCHR, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24
[49]  
RITZEN EM, 1992, NATO ASI SERIES H, V61, P154
[50]  
ROBINSON WP, 1991, AM J HUM GENET, V49, P1219